Phase II trial investigating the tolerability and preliminary efficacy of inecalcitol in patients with chronic lymphocytic leukaemia, not yet requiring immuno-chemotherapy but at high risk of disease progression.

Trial Profile

Phase II trial investigating the tolerability and preliminary efficacy of inecalcitol in patients with chronic lymphocytic leukaemia, not yet requiring immuno-chemotherapy but at high risk of disease progression.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2014

At a glance

  • Drugs Inecalcitol (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Feb 2014 Interim results reported in a Hybrigenics media release.
    • 04 Feb 2014 To date, 24 patients have been enrolled, according to a Hybridgenics media release.
    • 28 Jan 2014 Based on preliminary clinical data, inecalcitrol has been designated as an orphan drug for chronic lymphocytic leukaemia in Europe, according to a Hybrigenics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top